Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04949503

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN — Redbull-1  

Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Clinical Trial Summary

This study is a retrospective real-world study. In this study, we plan to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab .

Clinical Trial Description

This study is a retrospective real-world study. The diagnosis and treatment of patients, disease management, and information collection are completely dependent on the daily medical practice. In this study, we plan to select 5 to 8 hospitals nationwide to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab from January 2015 to December 2018. Patients included in the study will be followed up for survival. The main endpoint is 3-year overall survival (OS) rate; the secondary endpoint are 3-year progression-free survival (PFS) rate, 3-year Local-regional control (LRC) rate, objective response rate (ORR), disease control rate (DCR) and safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04949503
Study type Observational
Source Biotech Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase
Start date October 8, 2021
Completion date April 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03426657 - Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC Phase 2
Recruiting NCT05172245 - Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Phase 1
Completed NCT04870840 - Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Phase 1
Completed NCT04541355 - Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Phase 2
Recruiting NCT03649048 - Low-Dose Weekly vs High-Dose Cisplatin N/A
Recruiting NCT05724602 - Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05773079 - Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05861557 - Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05527782 - Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05376553 - Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 1
Withdrawn NCT03875053 - Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer N/A
Recruiting NCT04892173 - NBTXR3 With or Without Cetuximab in LA-HNSCC Phase 3
Withdrawn NCT05743270 - Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN Phase 2
Recruiting NCT06240689 - A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood Phase 2
Recruiting NCT04454489 - Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Phase 2
Completed NCT01689194 - Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT05245682 - Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer Early Phase 1
Recruiting NCT04947241 - Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC Phase 1
Recruiting NCT06129864 - A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy Phase 3